Q-omics provides the consensus-scored RN7SL832P profile across patient tissues and cancer cell-line models. RN7SL832P expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RN7SL832P is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, RN7SL832P RNA expression shows 18,005 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where RN7SL832P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RN7SL832P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RN7SL832P survival associations across molecular data types. RN7SL832P RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RN7SL832P RNA expression–survival associations across cancer types. High RN7SL832P expression shows unfavorable associations in ACC and BLCA, but favorable associations in PAAD, LUAD, UCS and LUSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RN7SL832P RNA expression.
This table summarizes RN7SL832P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RN7SL832P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RN7SL832P shows lower tumor expression in KIRC, THCA, KICH, BRCA and KIRP and higher tumor expression in BLCA. The KIRC box plot shows higher RN7SL832P RNA expression in normal versus tumor tissue (log2 FC = −1.024, t-test p < 0.001).
This table shows molecular features associated with RN7SL832P in patient tissues and cancer cell lines. In patient samples, RN7SL832P shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
